Part of the submissions that the MS Society has made have been related to changes that are being proposed by the Patented Medicine Prices Review Board. I flag that here because the theme we have in our recommendations is certainly around patient-centred coordinated approaches and a priority-setting framework for these sorts of things.
At the end of the day, any changes that are made in the landscape should not result in a reduction in choice. That's critical. When we talk about access, certainly the financial piece of that is important, but outcomes are equally important. Some of the difficulties we hear about from our community and others in the health charities sector is that Health Canada-approved disease-modifying therapies are not consistently available across this country. There are stories of people moving from one province to another to get the treatment that works for them if they do not have private health insurance, and that's a concern.